Our Studies

If you are interested in learning more information about our ongoing clinical trials, please contact us below.

ACTIVELY ENROLLING TRIALS BELOW:

  • oral medication in patients with heart failure with preserved ejection fraction.

  • Self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction

  • A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation

  • Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

  • Nasal Spray for patients with A-fib

  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

  • An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV

  • A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata

  • SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Testimonials

  • "I recently participated in a clinical research trial, under her expert tutelage. The consummate professional, was impressively knowledgeable with a relaxing, gracious manner. Savvy and considerate of my needs without forsaking meticulous attention to every detail surrounding her goal to obtain the best outcome of the trial, her attention never wavered. Her explanations were right on point, and she never hesitated to respond to my inquiries with clear, precise responses, always keeping her focus undistracted and fine-tuned. This charismatic young woman with excellent interpersonal skills and an elite clinical savoir-faire is an asset to FWD and the world of clinical research! Thanks, for a rewarding experience.

    - Research Trial Participant, Boca Raton, FL